Skip to Main Content

Shares of MediciNova (MNOV), a small biotech, rose sharply Monday, but for a reason that may not hold up to scientific scrutiny.

MediciNova announced the early termination of a mid-stage study because of positive results in patients with NASH, or nonalcoholic steatohepatitis, a fatty liver disease. MediciNova shares rose 20 percent to $12.33.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • A cheap way to cut triglycerides is to consume less sugar. Treating the symptoms of a bad diet is not good medicine but slipstreaming the soft drinks industry is probably excellent business

Comments are closed.